Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Upon authorization by the European Commission (EC), the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...

On Friday, Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) released topline results from the Phase 3 trial of the combined mRNA vaccine candidate against influenza and COVID-19 in healthy ...

Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula)* is FDA authorized under Emergency Use Authorization (EUA) to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory ...

Combo candidate showed good immune responses against COVID-19 and influenza A, but not influenza B Pfizer Inc. and BioNTech SE said Friday that a Phase 3 trial of their COVID-19-influenza combination ...

LONDON, July 10 (Reuters) - Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents, in ...

March 5 - Pfizer (PFE.N), opens new tab and BioNTech (22UAy.DE), opens new tab won a round in their legal battle with Moderna (MRNA.O), opens new tab over COVID-19 vaccine patents on Wednesday, ...

Thursday, the FDA granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...